1. Clinical Question
How have the regulatory status and safety profiles of commonly utilized peptides changed according to recent FDA updates and postmarketing surveillance data?
2. Evidence Snapshot
- Regulatory Shift: Multiple peptides, including BPC-157 and CJC-1295, categorized as Category 2 (significant safety risk) in 503A compounding.
- FAERS Data: Over 187,757 GLP-1 RA adverse event reports through 2023, identifying emerging signals such as NAION and pulmonary aspiration.
- Clinical Efficacy (Semaglutide): 14.9% weight loss (STEP 1) and 20% MACE reduction (SELECT).
- Clinical Efficacy (Tirzepatide): 22.5% weight loss (SURMOUNT-1); demonstrated superiority over semaglutide in SURMOUNT-5.
- Thymosin Alpha-1: Negative Phase III results for sepsis mortality; non-FDA approved status maintained.
3. What the Research Shows
Regulatory and Compounding Status As of March 2026, the FDA has significantly restricted the compounding of several peptides under Section 503A and 503B. BPC-157, TB-500, GHK-Cu, and GHRP-2 are currently listed as Category 2 bulk substances due to immunogenicity concerns and a lack of clinical safety data. Notably, BPC-157 is deemed to pose a significant safety risk and is ineligible for routine compounding.
Several nominations for compounding were withdrawn or removed in September 2024, including AOD-9604, CJC-1295, Ipamorelin, and Selank. While Thymosin Alpha-1 is approved as Zadaxin in over 35 countries, it remains non-FDA approved and is listed as a substance of concern under interim policy following its removal from the pending advisory review list in September 2024.
Safety Signals and Postmarketing Surveillance FAERS data for semaglutide indicates strong signals for gastrointestinal events, including nausea, vomiting, and delayed gastric emptying. The latter has led to new clinical concerns regarding pulmonary aspiration during general anesthesia, resulting in an updated Ozempic label in 2025.
More severe gastrointestinal signals include moderate signals for acute pancreatitis and cholelithiasis, and an emerging signal for intestinal obstruction/ileus. Beyond the GI system, an emerging signal for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) was identified with 96 cases through December 2024, prompting an EMA review in January 2025. Suicidal ideation is currently under FDA evaluation, though existing data do not support a risk higher than the background rate.
Clinical Trial Outcomes Phase III trials for semaglutide confirmed significant weight loss and cardiovascular benefit (20% MACE reduction). Tirzepatide demonstrated higher weight loss (22.5%) in SURMOUNT-1 and was found superior to semaglutide in the SURMOUNT-5 head-to-head trial. Retatrutide (Phase II) showed 24.2% weight loss at 12mg, with Phase III trials ongoing. Conversely, a Phase III trial for Thymosin Alpha-1 in sepsis yielded negative results, showing no reduction in mortality.
4. Mechanism
Based on the provided data, the specific biochemical pathways of action for these substances are not detailed beyond their clinical associations. Tesamorelin is documented to achieve an 18% reduction in visceral adipose tissue (VAT) in HIV lipodystrophy. Semaglutide and tirzepatide are associated with delayed gastric emptying, which contributes to gastrointestinal adverse events and may impact the absorption of oral medications.
5. Limitations of the Evidence
There is a notable lack of human exposure and safety data for several peptides including TB-500 and BPC-157. For compounds like Selank and Semax, while approved in Russia, there is a lack of FDA-recognized clinical data for their respective indications (anxiety and stroke).
Safety signals for NAION and pulmonary aspiration are emerging and require further investigation to establish definitive causality. Additionally, while FAERS provides a high volume of reports (e.g., 187,757 for GLP-1 RAs), these are spontaneous reports and may not reflect absolute incidence rates.
6. Clinical Takeaway
Physicians should note that many peptides previously available through compounding pharmacies are now classified as Category 2 substances due to immunogenicity and safety risks, effectively restricting their use in routine compounding. While semaglutide and tirzepatide show robust clinical efficacy in obesity and CV outcomes, emerging safety signals regarding NAION and perioperative aspiration risk require careful monitoring.
7. Sources
- FDA Regulatory Status Records (BPC-157, Thymosin Alpha-1, TB-500, AOD-9604, CJC-1295, Ipamorelin, Selank, Semax, GHK-Cu, GHRP-2)
- FAERS Safety Signal Database (Semaglutide 2023-2025)
- Clinical Trial Records: NCT03548935, NCT03574597, NCT04184622, NCT05024032, NCT04881706, NCT059290, NCT00451282, NCT02867267
This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.
Referenced Peptides
This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.